DELIVER phase III trial shows AstraZeneca Farxiga improved symptom burden and health-related quality of life in patients with mildly reduced or preserved ejection fraction
By, Admin1 min read
Share
New findings from a pre-specified analysis of DELIVER phase III trial data show that AstraZeneca
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
